从传统他汀及其联合治疗看调脂治疗的临床获益

摘要： 动脉粥样硬化性心血管疾病 （ASCVD） 是全球范围内主要的疾病负担， 亦是患者死亡的主要原因。既往大量关于他汀类药物调脂治疗的临床试验证实， 他汀类药物可有效降低 ASCVD 患者低密度脂蛋白胆固醇 （LDL-C） 水平、 全因死亡率和心血管病死亡率， 无 ASCVD 的患者亦可获益。然而， 目前无论是 ASCVD 高危患者还是无 ASCVD 的人群， 并未广泛应用降脂治疗。因此， 本文阐述了他汀类及其联合用药所带来的临床获益， 旨在增大受益人群， 改善预后。

New perspectives on cardiovascular benefits of conventional statins and their combination therapy for lipid regulation

Abstract: Atherosclerotic cardiovascular diseases (ASCVD) are the major causes of morbidity and mortality worldwide. Previous randomized controlled trials confirm that statin therapy can effectively reduce the level of low density lipoprotein cholesterol (LDL-C), all-cause and cardiovascular disease mortality in patients with and without ASCVD. However, there is no widespread use of lipid-lowering therapy to achieve the benefit in high risk patients with ASCVD and patients without ASCVD. Therefore, it is necessary to further elaborate the clinical benefits of statins and their combined use for lipid regulating therapy and increasing the beneficiaries.